IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer
ConclusionsIL17RB predicts the prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Source: Pathology Research and Practice - Category: Pathology Source Type: research